This Month
IV drips move from hospitals to luxury spas and hotels
Once just in medical centres, intravenous treatments have become a crossover sensation in the health, wellness and travel sphere – and not just for hangovers.
- Andrea Sachs
This former Young Rich Lister just spent $700k to alter his genes
Nick Bell’s first business failed, his next made him millions. The serial entrepreneur’s latest business venture involves helping people live longer.
- Julie-anne Sprague
April
Spotify’s CEO launches $350 body scans to fight disease, prolong life
The company that billionaire Daniel Ek founded, Neko Health, opened in Stockholm last year, and it is about to open in London.
- Bernhard Warner
- Breaking
- University
‘The right time to go’: Maskell to leave Melbourne University
Duncan Maskell, the University of Melbourne’s vice chancellor, will step down next year just halfway through his second five-year term.
- Julie Hare
Is it possible to find love without an app?
Online-dating fatigue is creating pressure for innovations to help humans discover love in real life, but hitting on strangers isn’t easy.
- Faith Hill
The rich love anti-ageing stem cell therapy, but does it really work?
The procedure is becoming a favourite for Hollywood A-listers and actors such as John Cleese. It is still under-researched, however – and could be dangerous.
- David Cox
Anteris Technologies launches $23m placement; Evolution on ticket
Fund managers were told Anteris would look to use up the 950,000 shares left under its annual placement capacity.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Medtech Atmo Biosciences shop raise at $55m valuation
Alium Capital Management, Japanese pharmaceuticals giant Otsuka Pharmaceutical and Breakthrough Victoria are set to cornerstone Atmo Biosciences $15 million equity raise.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Why picking ASX biotechs is mostly for the crazy brave
It’s a space with a reputation for rollercoaster returns and outlandish sales pitches, but some investors get lucky.
- Tom Richardson
March
- Exclusive
- Venture capital
From start-up star to near collapse at the ‘next Cochlear’
Seer Medical was feted from its inception in 2017, after developing a groundbreaking wearable device for epilepsy. Then it met the Victorian government.
- Patrick Durkin and Tom Richardson
Blood giant CSL works up $US1 billion-plus bond deal; banks mandated
CSL has a host of top-tier investment banks working on the deal, namely Bank of America, Citi, JPMorgan and HSBC.
- Sarah Thompson, Kanika Sood and Emma Rapaport
February
Why analysts love these eight medtech stocks
The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.
- Tom Richardson
- Opinion
- Software
What investors can learn from analysing R&D spending
High levels of R&D do not necessarily translate into increased returns on invested capital.
- Tony Boyd
January
Grifols sues Gotham City over ‘false’ short-seller report
CSL’s rival Grifols is taking its short-seller, Gotham City, to court saying the “defendants crossed the line”.
- Chris Dolmetsch
Mesoblast surges on FDA ‘rare paediatric disease’ designation
Shares in Australian biopharmaceutical company Mesoblast jumped 25 per cent after Revascor was recognised as a potential treatment for heart disease in babies.
- Joanna Mather
- Opinion
- Chanticleer
Why $3b Aussie darling Telix needs to grow wings
If Telix wants to truly mix it with the big players, it needs to be closer to those that can fund it.
- Anthony Macdonald
December 2023
- Exclusive
- Funding
New fund targets companies battered by market doubts
Record low biotech valuations have prompted a new VC investor to start shopping with a planned $200 million fund.
- Jessica Sier
Soul Patts-backed IPO hopeful Nicolab back in front of investors
The Amsterdam-based medtech is back on the fund-raising trail just seven months after its last cash call.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Mesoblast taps Bell Potter for $98m equity raising
The biotech company launched its latest raising on Friday morning to fund clinical trials.
- Sarah Thompson, Kanika Sood and Emma Rapaport
October 2023
The key to this biotech’s tilt at US fortune is pure pigs
A Perth-based regenerative medicine company is preparing for a major expansion into the US market with a unique “collagen velcro” sourced from Australian pigs that repairs severed nerves.
- Tom Rabe